10.70
+0.63(+6.26%)
Currency In USD
| Previous Close | 10.07 |
| Open | 10.19 |
| Day High | 10.78 |
| Day Low | 10.03 |
| 52-Week High | 18.9 |
| 52-Week Low | 9.97 |
| Volume | 5.08M |
| Average Volume | 1.97M |
| Market Cap | 1.05B |
| PE | -22.29 |
| EPS | -0.48 |
| Moving Average 50 Days | 15.92 |
| Moving Average 200 Days | 13.79 |
| Change | 0.63 |
If you invested $1000 in ARS Pharmaceuticals, Inc. (SPRY) since IPO date, it would be worth $428 as of September 09, 2025 at a share price of $10.7. Whereas If you bought $1000 worth of ARS Pharmaceuticals, Inc. (SPRY) shares 3 years ago, it would be worth $2,061.66 as of September 09, 2025 at a share price of $10.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-wo
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to a
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewswire Inc.
Jul 18, 2025 1:25 PM GMT
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in